|Articles|September 25, 2016
Tufts CSDD Releases Findings from Diabetes Study
September 26, 2016
Advertisement
According to results of a new study by the Tufts Center for the Study of Drug Development, the development process for new diabetes and non-diabetes endocrine drugs is riskier compared to all drug development. The study examined the development pathways and characteristics of 27 diabetes and 34 non-diabetes endocrine drugs.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Pharmaceutical Executive Daily: FDA Pilot Targets Faster Early-Stage Drug Trial Starts
2
The Economics of the 340B Drug Pricing Program: Strategic Imperatives for the Life Sciences Industry in 2026
3
FDA Pilot Targets Faster Early-Stage Drug Trial Starts
4
The Next Evolution of Class of Trade: Why Customer Identity Is Becoming Market Access’s Hardest Problem
5